Swiss Industries Face Tariff Turmoil Amid Trump Trade Decisions

The Swiss manufacturing sector faces significant challenges as a result of a new 39% U.S. tariff, more than double that of most E.U. imports. Swiss manufacturers fear tens of thousands of job losses and advocate for continued negotiation to reduce tariffs, although the pharmaceutical industry is exempt.

On Friday, Swiss manufacturers expressed grave concerns about potential job losses after U.S. President Donald Trump imposed a high tariff rate as part of his global trade policy shift. Set at 39%, much higher than the 15% for most European Union imports, the tariff could devastate job security in Switzerland.

The new tariff, a substantial increase from an already controversial 31%, caught the small European nation off-guard, considering the U.S. as its top market for watches, jewelry, and chocolates. Swiss companies are appealing for continued talks with U.S. representatives to mitigate the impact of this abrupt policy change.

Exempt from this drastic measure is Switzerland's pivotal pharmaceuticals sector, easing concerns for major players like Roche and Novartis. However, the pressure to negotiate persists, with significant economic ties between the countries: Switzerland is the seventh-largest investor in the U.S. and has a hefty trade surplus.